SARSCoV-2 antibody prevalence and titers in persons living with HIV cared for at a large tertiary reference center in Mexico City

Soto-Nava, Maribel; Dávila-Conn, Vanessa; Venancio-Rocha, Juan P.; García-Esparza, Pedro; Tapia-Trejo, Daniela; Hernández-Juan, Ramón; Zarza-Sánchez, Eduardo; Murakami-Ogasawara, Akio; Ávila-Ríos, Santiago

doi:10.1186/s12985-023-02261-2

Virology Journal

Table 1 General characteristics of PLWHIV participating in the study

From: SARSCoV-2 antibody prevalence and titers in persons living with HIV cared for at a large tertiary reference center in Mexico City

		Total		Prevalent Cases		Incident Cases		Non-Cases		p value^b
		n	%^a	n	%^a	n	%^a	n	%^a	p value^b
Age (years)	< 50	566	70.6	181	77.7	101	76.5	284	65	< 0.001
Age (years)	≥ 50	236	29.4	52	22.3	31	23.5	153	35
Sex at birth	Male	685	85.6	201	86.3	111	84.7	373	85.6	0.999
Sex at birth	Female	115	14.4	32	13.7	20	15.3	63	14.5
Gender	Cisgender Men	659	82.2	188	80.7	107	81.1	364	83.3	0.527
	Cisgender Women	136	17	42	18	23	17.4	71	16.3
	Transgender Women	3	0.4	1	0.4	1	0.8	1	0.2
	Non-binary	2	0.2	0	0	1	0.8	1	0.2
	Other	2	0.2	2	0.9	0	0	0	0
State of residency	Mexico City	550	68.8	147	63.1	91	69.5	312	71.6	0.117
	State of Mexico	190	23.8	70	30	29	22.1	91	20.9
	Other^c	60	7.5	16	6.9	11	8.4	33	7.6
Municipality	North Mexico City	92	11.5	24	10.3	13	9.9	55	12.7	0.163
	South Mexico City	171	21.5	39	16.8	27	20.6	105	24.2
	East Mexico City	133	16.7	42	18.1	23	17.6	68	15.7
	West Mexico City	151	18.9	41	17.7	28	21.4	82	18.9
	State of Mexico	190	23.8	70	30.2	29	22.1	91	21
	Other^d	60	7.5	16	6.9	11	8.4	33	7.6
Use of public transport	No use	352	43.9	87	37.3	63	47.7	202	46.2	0.042
	Subway	332	41.4	103	44.2	48	36.4	181	41.4
	Taxi/Uber	24	3	5	2.2	4	3	15	3.4
	Other^e	94	11.7	38	16.3	17	12.9	39	8.9
Travel by plane during the pandemic	Yes	141	17.6	46	19.7	23	17.4	72	16.5	0.353
Travel by plane during the pandemic	No	661	82.4	187	80.3	109	82.6	365	83.5
Vaccinated against COVID-19	Yes	279	34.8	94	59.7	31	23.5	154	35.2	0.520
Vaccinated against COVID-19	No	523	65.2	139	40.3	101	76.5	283	64.8
Type COVID-19 vaccine	BNT162b2 (Pfizer/BioNTech)	77	27.7	30	20.1	12	16.9	82	28.2	0.001
	AZD1222 (AstraZeneca)	128	46	84	56.4	40	56.3	134	46.1
	Ad5-nCoV (Cansino)	13	4.7	6	4.03	7	9.9	13	4.5
	Gam-COVID-Vac (Sputnik-V)	45	16.2	19	12.8	8	11.3	49	16.8
	CoronaVac (Sinovac)	6	2.2	8	5.4	4	5.6	4	1.4
	Ad26.COV2-S (Janssen)	5	1.8	0	0	0	0	7	2.4
	Spikevax (Moderna)	4	1.4	2	1.3	0	0	2	0.7

^aColumn percentages are shown
^bFisher exact test, two-sided p values are shown comparing all positive cases (prevalent cases + incident cases) vs non-cases. Statistically significant P values (≤ 0.05) are in bold
^cIncludes other states of Mexico
^dIncludes municipalities in other states
^eIncludes bus rapid transit (metrobus), bus, minibus and trolleybus

Back to article page

ISSN: 1743-422X

Contact us

Submission enquiries: journalsubmissions@springernature.com